Cardiovascular disease in patients with schizophrenia

Kritharides, Leonard; Chow, Vincent; Lambert, Tim

doi:10.5694/mja17.00258

Cited by 12 publications

(15 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Schizophrenia is a severe and persistent mental illness that is ‘associated with high levels of social burden and cost, as well as an incalculable amount of individual pain and suffering’ (Barbato, n.d.). In addition to the social and occupational dysfunction, it has been noted that patients with schizophrenia die over 20 years earlier than the general population with most of the excess mortality due to premature cardiovascular death (Kritharides et al, 2017)…”

Section: Schizophrenia Spectrum Disorders Mhealth and Their Ethical mentioning

confidence: 99%

“…Schizophrenia is a severe and persistent mental illness that is 'associated with high levels of social burden and cost, as well as an incalculable amount of individual pain and suffering' ( Barbato, n.d.). In addition to the social and occupational dysfunction, it has been noted that patients with schizophrenia die over 20 years earlier than the general population with most of the excess mortality due to premature cardiovascular death (Kritharides et al, 2017) The treatment for patients experiencing one of the schizophrenia spectrum or other psychotic disorders is multifaceted and requires a biopsychosocial treatment approach. Unfortunately, access to some treatment options and supportive services may be limited.…”

Section: Schizophrenia Spectrum and Other Psychotic Disordersmentioning

confidence: 99%

See 1 more Smart Citation

mHealth for schizophrenia spectrum disorders management: A systematic review

Chivilgina

Wangmo

Elger

et al. 2020

Int J Soc Psychiatry

View full text Add to dashboard Cite

Background: Various types of computational technologies can be used to access, store and wirelessly share private and sensitive user-related information. The ‘big data’ provided by these technologies may enable researchers and clinicians to better identify behavioral patterns and to provide a more personalized approach to care. The information collected, however, can be misused or potentially abused, and therefore could be detrimental to the very people who provided their medical data with the hope of improving care. This article focuses on the use of emerging mobile technologies that allow the collection of data about patients experiencing schizophrenia spectrum and related disorders. Schizophrenia has been recognized by the Sustainable Development Goals of the United Nations for its burden on our health care system and society [1]. Our analysis provides an overview of the range of available mobile technologies for people with schizophrenia and related conditions along with the technology’s reported capabilities and limitations, and efficacy of mHealth interventions based on the data from articles. Thus, the focus of this review is first and foremost to update the scope of existing technologies as previous systematic reviews such as the ones by Alvarez-Jimenez et al. and by Firth and Torous are outdated [2, 3]. Although we also examine the ethical issues arising from the use of these technologies, for an in-depth analysis of the ethical implications of mobile Health technologies (mHealth), we refer the readers to our follow-up article. In terms of the ubiquitous availability of technology on the internet, our article summarizes significant information for mental health specialists and apprises the reader about the existence of these technologies. Objectives: In terms of the ubiquitous availability of technology on the internet, our article summarizes significant information for mental health specialists and apprises the reader about the existence of these technologies.

show abstract

Section: Schizophrenia Spectrum Disorders Mhealth and Their Ethical mentioning

confidence: 99%

Section: Schizophrenia Spectrum and Other Psychotic Disordersmentioning

confidence: 99%

mHealth for schizophrenia spectrum disorders management: A systematic review

Chivilgina

Wangmo

Elger

et al. 2020

Int J Soc Psychiatry

View full text Add to dashboard Cite

show abstract

“…One of the leading causes of premature death in patients with schizophrenia is cardiovascular disease [5][6][7]. Among the risk factors for cardiovascular disease, obesity is prominent and very common [8,9].…”

Section: Introductionmentioning

confidence: 99%

Schizophrenia patients with a metabolically abnormal obese phenotype have milder negative symptoms

Wang

Liu

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Schizophrenia patients with a metabolically abnormal obese (MAO) phenotype have been shown poor cardiovascular outcomes, but the characteristics of their current mental symptoms have not been characterized. This study mainly explored the psychiatric symptoms of schizophrenia patients with the MAO phenotype.Methods: A total of 329 patients with schizophrenia and 175 sex- and age-matched people without schizophrenia from Anhui Province in China were enrolled. The Positive and Negative Syndrome Scale (PANSS) was used to evaluate the mental symptoms of the schizophrenia patients. The MAO phenotype was defined as meeting 1-4 metabolic syndrome criteria (excluding waist circumference) and having a body mass index (BMI) ≥ 28 kg/m 2 . And, metabolically healthy normal-weight (MHNW) phenotype was defined as meeting 0 criteria for metabolic syndrome and 18.5 ≤ BMI < 24 kg/m 2.Results: Overall, 15.8% of the schizophrenia patients and 9.1% of the control group were consistent with the MAO phenotype, and the prevalence of MAO in the schizophrenia group was higher than that in the control group. Among the patients with schizophrenia, the MAO group had lower negative factor, cognitive factor and total PANSS scores than the MHNW group. However, when confounding factors were controlled, only the negative factor remained lower. The correlation analysis showed that the MAO phenotype was strongly correlated with C-peptide and insulin levels.Conclusion: we found that schizophrenia patients with the MAO phenotype had reduced negative symptoms, which may indicate an internal mechanism linking metabolic disorders and negative symptoms.Trial registration: This study was registered in the China Clinical Trial Registration Center (No. chiCTR 1800017044)

show abstract

“…Other healthcare factors include side effects from anti-psychotic medications which are recognized as contributors to the development of obesity, metabolic syndrome and possibly autonomic nervous system dysfunction 4 . To add insult to injury, patients suffering from schizophrenia who experience an ACS have been noted to receive suboptimal medical care and are half as likely to undergo coronary revascularisation compared to patients with no mental illness 12,13 . This strongly highlights healthcare inequality when it comes to cardiac management and augments the problem by creating a 'health care paradox', where patients who need care the most, are less likely to receive it.…”

mentioning

confidence: 99%

“…In addition, reviews of antipsychotic medications should take place on a regular basis in an attempt to choose the agent/dosage with the least possible physical side effects. Finally, the observation of reduced revascularisation rates in this patient group must be reviewed and tackled by tailoring revascularisation strategies, follow up and cardiac rehabilitation arrangements as well as intensifying efforts to manage risk factors by engaging with primary care services and keeping a closer eye on this high risk group 13 .…”

mentioning

confidence: 99%

Coronary artery disease and schizophrenia: the interplay of heart and mind

Protty

2019

European Heart Journal - Quality of Care and Clinical Outcomes

View full text Add to dashboard Cite

Cardiovascular disease in patients with schizophrenia

Cited by 12 publications

References 2 publications

mHealth for schizophrenia spectrum disorders management: A systematic review

mHealth for schizophrenia spectrum disorders management: A systematic review

Schizophrenia patients with a metabolically abnormal obese phenotype have milder negative symptoms

Coronary artery disease and schizophrenia: the interplay of heart and mind

Contact Info

Product

Resources

About